非小細胞肺がん治療薬の世界市場（～2026年）

• 英文タイトル：Global Non-small Cell Lung Cancer Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04010
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は非小細胞肺がん治療薬のグローバル市場について調査・分析したレポートです。種類別（Alimta、Iressa、Avastin、Tarceva、Zykadia、Tagrisso、Xalkori、Cyramza、Opdivo、Alecensa）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別非小細胞肺がん治療薬の競争状況、市場シェア
・世界の非小細胞肺がん治療薬市場：種類別市場規模 2015年-2020年（Alimta、Iressa、Avastin、Tarceva、Zykadia、Tagrisso、Xalkori、Cyramza、Opdivo、Alecensa）
・世界の非小細胞肺がん治療薬市場：種類別市場規模予測 2021年-2026年（Alimta、Iressa、Avastin、Tarceva、Zykadia、Tagrisso、Xalkori、Cyramza、Opdivo、Alecensa）
・世界の非小細胞肺がん治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック）
・世界の非小細胞肺がん治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック）
・北米の非小細胞肺がん治療薬市場分析：米国、カナダ
・ヨーロッパの非小細胞肺がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの非小細胞肺がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の非小細胞肺がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの非小細胞肺がん治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：GlaxoSmithKline、Novartis、AstraZeneca、Roche、Bristol-Myers Squibb、Pfizer、Eli Lilly、Sanofi
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Non-small Cell Lung Cancer Therapeutics Market
The global Non-small Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Non-small Cell Lung Cancer Therapeutics Scope and Market Size
Non-small Cell Lung Cancer Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi

Market segment by Type, the product can be split into
Alimta
Iressa
Avastin
Tarceva
Zykadia
Tagrisso
Xalkori
Cyramza
Opdivo
Alecensa
Market segment by Application, split into
Hospital
Clinic

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alimta
1.4.3 Iressa
1.4.4 Avastin
1.4.5 Tarceva
1.4.6 Zykadia
1.4.7 Tagrisso
1.4.8 Xalkori
1.4.9 Cyramza
1.4.10 Opdivo
1.4.11 Alecensa
1.5 Market by Application
1.5.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2015-2026)
2.2 Global Non-small Cell Lung Cancer Therapeutics Growth Trends by Regions
2.2.1 Non-small Cell Lung Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-small Cell Lung Cancer Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Market Size
3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
3.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2019
3.3 Non-small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
3.4 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
3.5 Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
6.2 Non-small Cell Lung Cancer Therapeutics Key Players in North America (2019-2020)
6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
7.2 Non-small Cell Lung Cancer Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
8.2 Non-small Cell Lung Cancer Therapeutics Key Players in China (2019-2020)
8.3 China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
8.4 China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
9.2 Non-small Cell Lung Cancer Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
9.4 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
10.2 Non-small Cell Lung Cancer Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
11.2 Non-small Cell Lung Cancer Therapeutics Key Players in India (2019-2020)
11.3 India Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
11.4 India Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
12.2 Non-small Cell Lung Cancer Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
13.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
13.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 AstraZeneca
13.3.1 AstraZeneca Company Details
13.3.2 AstraZeneca Business Overview
13.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
13.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.3.5 AstraZeneca Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
13.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
13.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
13.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 Eli Lilly
13.7.1 Eli Lilly Company Details
13.7.2 Eli Lilly Business Overview
13.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
13.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.7.5 Eli Lilly Recent Development
13.8 Sanofi
13.8.1 Sanofi Company Details
13.8.2 Sanofi Business Overview
13.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
13.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
13.8.5 Sanofi Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Non-small Cell Lung Cancer Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
Table 3. Ranking of Global Top Non-small Cell Lung Cancer Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alimta
Table 6. Key Players of Iressa
Table 7. Key Players of Avastin
Table 8. Key Players of Tarceva
Table 9. Key Players of Zykadia
Table 10. Key Players of Tagrisso
Table 11. Key Players of Xalkori
Table 12. Key Players of Cyramza
Table 13. Key Players of Opdivo
Table 14. Key Players of Alecensa
Table 15. Global Non-small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Non-small Cell Lung Cancer Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Non-small Cell Lung Cancer Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Non-small Cell Lung Cancer Therapeutics Market Share by Regions (2015-2020)
Table 19. Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Non-small Cell Lung Cancer Therapeutics Market Growth Strategy
Table 25. Main Points Interviewed from Key Non-small Cell Lung Cancer Therapeutics Players
Table 26. Global Non-small Cell Lung Cancer Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 27. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players (2015-2020)
Table 28. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2019)
Table 29. Global Non-small Cell Lung Cancer Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
Table 32. Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 35. Global Non-small Cell Lung Cancer Therapeutics Market Size Share by Type (2015-2020)
Table 36. Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2021-2026)
Table 37. Global Non-small Cell Lung Cancer Therapeutics Market Size Share by Application (2015-2020)
Table 38. Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. Global Non-small Cell Lung Cancer Therapeutics Market Size Share by Application (2021-2026)
Table 40. North America Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 42. North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. North America Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 44. North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. North America Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 46. Europe Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 48. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 50. Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 52. China Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 53. China Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 54. China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. China Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 56. China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. China Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 58. Japan Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 60. Japan Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 62. Japan Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 66. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 68. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 70. India Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 71. India Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 72. India Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. India Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 74. India Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. India Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Non-small Cell Lung Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Non-small Cell Lung Cancer Therapeutics Market Share (2019-2020)
Table 78. Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Non-small Cell Lung Cancer Therapeutics Market Share by Type (2015-2020)
Table 80. Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Non-small Cell Lung Cancer Therapeutics Market Share by Application (2015-2020)
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Product
Table 85. GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 86. GlaxoSmithKline Recent Development
Table 87. Novartis Company Details
Table 88. Novartis Business Overview
Table 89. Novartis Product
Table 90. Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 91. Novartis Recent Development
Table 92. AstraZeneca Company Details
Table 93. AstraZeneca Business Overview
Table 94. AstraZeneca Product
Table 95. AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 96. AstraZeneca Recent Development
Table 97. Roche Company Details
Table 98. Roche Business Overview
Table 99. Roche Product
Table 100. Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 101. Roche Recent Development
Table 102. Bristol-Myers Squibb Company Details
Table 103. Bristol-Myers Squibb Business Overview
Table 104. Bristol-Myers Squibb Product
Table 105. Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 106. Bristol-Myers Squibb Recent Development
Table 107. Pfizer Company Details
Table 108. Pfizer Business Overview
Table 109. Pfizer Product
Table 110. Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 111. Pfizer Recent Development
Table 112. Eli Lilly Company Details
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Product
Table 115. Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 116. Eli Lilly Recent Development
Table 117. Sanofi Business Overview
Table 118. Sanofi Product
Table 119. Sanofi Company Details
Table 120. Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020) (Million US$)
Table 121. Sanofi Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-small Cell Lung Cancer Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Alimta Features
Figure 3. Iressa Features
Figure 4. Avastin Features
Figure 5. Tarceva Features
Figure 6. Zykadia Features
Figure 7. Tagrisso Features
Figure 8. Xalkori Features
Figure 9. Cyramza Features
Figure 10. Opdivo Features
Figure 11. Alecensa Features
Figure 12. Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
Figure 13. Hospital Case Studies
Figure 14. Clinic Case Studies
Figure 15. Non-small Cell Lung Cancer Therapeutics Report Years Considered
Figure 16. Global Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global Non-small Cell Lung Cancer Therapeutics Market Share by Regions: 2020 VS 2026
Figure 18. Global Non-small Cell Lung Cancer Therapeutics Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global Non-small Cell Lung Cancer Therapeutics Market Share by Players in 2019
Figure 21. Global Top Non-small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Therapeutics as of 2019
Figure 22. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Therapeutics Revenue in 2019
Figure 23. North America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America Non-small Cell Lung Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Bottom-up and Top-down Approaches for This Report
Figure 31. Data Triangulation
Figure 32. Key Executives Interviewed

以下、関連資料のご紹介

肺がん治療薬の世界市場（～2026年）

Global Lung Cancer Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY12552 2020年11月25日 96Pages
当調査資料は肺がん治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法、標的療法、薬物、手術、放射線療法）市場規模、用途別（早期・中期肺がん治療、進行性肺がん治療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

肺がんリキッドバイオプシーの世界市場（～2026年）

Global Lung Cancer Liquid Biopsy Market Size, Status and Forecast 2020-2026
MRC2-11QY12550 2020年11月25日 91Pages
当調査資料は肺がんリキッドバイオプシーのグローバル市場について調査・分析したレポートです。種類別（CTC、CtDNA、エクソソーム・RNA、その他）市場規模、用途別（クリニック、病院、診療所研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

スモールセルネットワークの世界市場（～2026年）

Global Small Cell Networks Market Size, Status and Forecast 2020-2026
MRC2-11QY04653 2020年11月20日 93Pages
当調査資料はスモールセルネットワークのグローバル市場について調査・分析したレポートです。種類別（フェムトセル、ピコセル、マイクロセル、メトロセル）市場規模、用途別（政府、小売、教育、エネルギー・電力、金融、医療、ホスピタリティ、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フラン...

基底細胞がん（BCC）治療薬の世界市場（～2026年）

Global Basal Cell Carcinoma Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY11023 2020年11月25日 91Pages
当調査資料は基底細胞がん（BCC）治療薬のグローバル市場について調査・分析したレポートです。種類別（手術、放射線療法、光線力学療法、薬物）市場規模、用途別（小売薬局、病院薬局、がん研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

肺がん診断検査の世界市場（～2026年）

Global Lung Cancer Diagnostic Tests Market Size, Status and Forecast 2020-2026
MRC2-11QY12548 2020年11月25日 94Pages
当調査資料は肺がん診断検査のグローバル市場について調査・分析したレポートです。種類別（イムノアッセイ、フローサイトメトリー、迅速検査、分子アッセイ、組織アレイ、循環腫瘍細胞、薬理診断、バイオマーカー、その他診断方法）市場規模、用途別（精密医療、個別化医療、がんモニタリング）市場規模、地域別（北米、米...

がん幹細胞治療の世界市場（～2026年）

Global Cancer Stem Cell Therapy Market Size, Status and Forecast 2020-2026
MRC2-11QY11233 2020年11月25日 92Pages
当調査資料はがん幹細胞治療のグローバル市場について調査・分析したレポートです。種類別（自家幹細胞移植、同種幹細胞移植、同系幹細胞移植、その他）市場規模、用途別（病院、クリニック、医学研究機関、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...

DAS・スモールセル導入サービスの世界市場（～2026年）

Global DAS & Small Cell Deploy Service Market Size, Status and Forecast 2020-2026
MRC2-11QY11560 2020年11月25日 98Pages
当調査資料はDAS・スモールセル導入サービスのグローバル市場について調査・分析したレポートです。種類別（分散アンテナシステム（DAS）、スモールセル）市場規模、用途別（駅、地下鉄、空港、オフィスビル、モール、スタジアム、病院、公園、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

高度腎細胞癌治療薬の世界市場（～2026年）

Global Advanced Renal Cell Carcinoma Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY13590 2020年11月30日 125Pages
当調査資料は高度腎細胞癌治療薬のグローバル市場について調査・分析したレポートです。種類別（放射線療法、化学療法、ホルモン療法、治験療法）市場規模、用途別（病院、がん研究所、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

間質細胞由来因子1の世界市場（～2026年）

Global Stromal Cell Derived Factor 1 Market Insights and Forecast to 2026
MRC2-11QY10220 2020年11月25日 116Pages
当調査資料は間質細胞由来因子1のグローバル市場について調査・分析したレポートです。種類別（131-H12、1143-H1、ドシパルスタットナトリウム、ゲニステイン、その他）市場規模、用途別（冠状動脈疾患、重症下肢虚血、原発性免疫不全、脳卒中、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、...

ペプチド癌治療薬の世界市場（～2026年）

Global Peptide Based Cancer Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04203 2020年11月20日 99Pages
当調査資料はペプチド癌治療薬のグローバル市場について調査・分析したレポートです。種類別（ゴセレリン、ボルテゾミブ、リュープロレリン、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

肺がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Lung Cancer Therapeutics Market The global Lung Cancer Therapeutics market size is projected to reach US$ 15800 million by 2026, from US$ 14180 million in 2020, at a CAGR of 10.6%% during 2021-2026. Global Lung Cancer Therapeutics Scope and Market Size Lung Cance…
スモールセルネットワークの世界市場（～2026年） Small cells are low-powered cellular radio access nodes that operate in licensed and unlicensed spectrum that have a range of 10 meters to a few kilometers. They are "small" compared to a mobile macrocell, partly because they have a shorter range and partly because they typically handle fewer concur…
肺がんリキッドバイオプシーの世界市場（～2026年） Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. CtDNA and CTCs have been the most explored technologies for commercial applications up to the present time. Market Analysis and Insigh…
DAS・スモールセル導入サービスの世界市場（～2026年） DAS, is a network of spatially separated antenna nodes connected to a common source via a transport medium that provides wireless service within a structure. Small cells are low-powered cellular radio access nodes that operate in licensed and unlicensed spectrum that have a range of 10 meters to a f…
基底細胞がん（BCC）治療薬の世界市場（～2026年） Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…